Pure Global AI
NCT05798455Not yet recruiting

Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma

Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma: An Open-label Single-arm Phase 1b/2 Trial
Tabriz University of Medical SciencesPhase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
Sodium Pentaborate
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tabriz University of Medical Sciences
Location
Tabriz, Iran
Timeline & enrollment
Phase
Phase 1/2
Start date
May 22, 2023
End date
May 22, 2026
Enrollment
30 participants
Primary outcome

Maximum tolerated dose (MTD) and/or recommended dose,Objective response rate

Summary

This study investigates the safety and efficacy of sodium pentaborate pentahydrate in
 patients with advanced renal cell carcinoma.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05798455
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05798455 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Tabriz University of Medical Sciences and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.